Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management

被引：0
作者：
Yok-Ai Que
Frederik Delodder
Idris Guessous
Rolf Graf
Martha Bain
Thierry Calandra
Lucas Liaudet
Philippe Eggimann
机构：
[1] University Hospital Medical Center (CHUV) and University of Lausanne,Department of Intensive Care Medicine
[2] University Hospital Medical Center (CHUV) and University of Lausanne,Community Prevention Unit, Institute of Social and Preventive Medicine
[3] Geneva University Hospitals,Unit of Population Epidemiology, Division of Primary Care Medicine, Department of Community Medicine, Primary Care, and Emergency Medicine
[4] University Hospital,Swiss Hepato
[5] University Hospital Medical Center (CHUV) and University of Lausanne,Pancreatico
来源：
Critical Care | / 16卷
关键词：
Septic Shock; Severe Sepsis; Intensive Care Unit Admission; Sequential Organ Failure Assessment; Procalcitonin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 281 条
[1]  
Dellinger RP(2008)Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Crit Care Med 36 296-327
[2]  
Levy MM(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-709
[3]  
Carlet JM(2006)Sepsis in European intensive care units: results of the SOAP study Crit Care Med 34 344-353
[4]  
Bion J(2009)International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2323-2329
[5]  
Parker MM(1988)Treatment of gram-negative septic shock with human IgG antibody to J Infect Dis 158 312-319
[6]  
Jaeschke R(1998) J5: a prospective, double-blind, randomized trial Lancet 351 929-933
[7]  
Reinhart K(2004)Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group Crit Care Med 32 332-341
[8]  
Angus DC(2003)Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial N Engl J Med 348 138-150
[9]  
Brun-Buisson C(2003)The pathophysiology and treatment of sepsis Shock 20 295-302
[10]  
Beale R(2011)Clinical trial design and outcomes in patients with severe sepsis Crit Care Clin 27 241-251
12345678910